Semaglutide one month results: the truth behind the first four weeks

The biggest myth about month one: that visible weight loss means it is working, and absence means it is not

A lot of people reach the end of their first four weeks and feel quietly worried. The scale has not moved as far as they hoped, and they have read anecdotes online about dramatic early losses. The honest thing to say here is this: those anecdotes are real, but they are not the norm, and they are rarely occurring at the starting dose.

Wegovy (semaglutide injection) follows a titration schedule set by the prescriber. The first dose, 0.25 mg weekly, is prescribed to reduce the risk of nausea and other gastrointestinal side effects, not as a therapeutic weight-loss dose. The timeline for Wegovy to produce consistent weight loss runs over months, not weeks. Expecting meaningful scale movement in the first month, at the lowest dose, is a little like expecting a car to accelerate at walking pace. The engine is running; it simply has not been asked to do what it will eventually do.

The STEP 1 trial, which studied semaglutide 2.4 mg over 68 weeks and is published in the New England Journal of Medicine, found an average weight reduction of approximately 15% from baseline. That figure accumulated across more than a year of treatment, titrating through doses. Month one is step one of that journey, meaningful, but not the chapter where the headline numbers appear.

What is actually happening in your body during the first four weeks

Semaglutide is a GLP-1 receptor agonist. It acts on receptors involved in appetite signalling, slows the rate at which the stomach empties and increases the sense of fullness after eating. At 0.25 mg, those effects are present but modest. The dose is calibrated to be tolerable, which is the right priority when you are starting something new.

What many people do notice in month one is a shift in appetite rather than a dramatic number on the scale. Portion sizes feel more manageable. The urge to eat between meals is quieter. Some people lose a small amount of weight; some find the scale barely moves at all during the adjustment period. Both are within normal range. If you want to understand what to expect at this early stage, reading about semaglutide 1 month results can help set a realistic picture before you draw any conclusions. The broader picture of semaglutide results across clinical trials makes clear that meaningful weight reduction tends to emerge from month two or three onwards, when the dose has increased and the body has settled.

The most commonly reported side effects in the early weeks are nausea, loose stools, constipation, indigestion and fatigue. These are generally mild to moderate and tend to improve as treatment continues. The NHS's medicines information for semaglutide covers what to watch for and when to seek medical advice, it is worth reading before you start, not after a side effect surprises you.

What one month of data is genuinely useful for

Even if the scale result is modest, the first month is not wasted time. It establishes your tolerance, confirms the medicine suits you, and gives your prescriber something concrete to work with before a dose increase is considered. At nume (sorry, at Wegovy) no, let us be direct: at nume, a GPhC-registered Independent Prescriber reviews your case before every repeat order. A real clinician reads your notes, not software. That review matters most at the point a dose change is being considered.

For people who want to track their own progress honestly, month one is also useful for noticing behavioural shifts. Are you eating less without forcing it? Are you stopping sooner at meals? These signals often appear before the scale catches up, and they are consistent with how semaglutide is understood to work. Weight loss from a GLP-1 medicine is not the same as a crash diet, it tends to move more slowly and, trial data suggest, hold more durably.

If you are thinking about what month two or three might look like, semaglutide two-month results tend to be more pronounced as the dose reaches a more active level. The trajectory matters more than any single snapshot. Progress questions and any concerns about side effects should go to your prescriber, who can adjust or advise accordingly.

The cost question and what belongs in it

One month in is also when some people start weighing up whether treatment is worth continuing, and cost naturally enters that calculation. Semaglutide for weight management is a private prescription in most cases, it is not widely available on the NHS yet, and the Wegovy price comparison across UK providers varies considerably depending on what each service includes. The right question is not simply which provider charges least, but what that price actually covers: clinical review, ongoing prescriber support, and genuine supply-chain sourcing all carry weight alongside the number itself.

At nume, one transparent price includes consultation, prescription, and free next-working-day delivery. There are no subscriptions and no hidden charges. That is not a claim to being the cheapest option; it is a different proposition entirely. Treatment pricing is shown on our weight-loss treatments page.